Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Import to Russia (November 2018) January 21, 2019

Monday, January 21, 2019

Between January and November 2018, Russia imported 475.3 bln RUB worth of ready-made pharmaceutical drugs (free circulation prices, VAT included), which is in monetary terms 0.5% higher than that of the same period of 2017, and 97.3 bln RUB worth of in-bulk drugs, which is 13.6% higher than that of the same period of 2017. The total dynamics in monetary terms are +2.5%.

In physical terms, Russia imported 1.7 bln units of ready-made pharmaceuticals, which is 8.2% lower than that of the same period of 2017, and 3.8 bln minimum dosage units (MDU) of in-bulk pharmaceuticals, which is nearly 3% lower than that of the same period of 2017. In November 2018, Russia imported 264 mln MDUs of in-bulk pharmaceuticals, which is 35% lower than that of November 2018. Between January and November 2017, Russia imported 34.9 bln MDUs of pharmaceutical drugs (dynamics of -6.1%.)

Among the top 30 trademarks of ready-made pharmaceuticals with the biggest import volume over the period in monetary terms, anti-HIV drug Tivicay by Viiv Healthcare has the highest dynamics (18 times increase.) Nurofen by Reckitt has the worst dynamics (-23%), which is due to a lower import volume in physical terms.

As for in-bulk drugs, anti-tumor Imbruvica by Johnson & Johnson appeared on the Russian market in January 2018. It is packaged at the facilities of Pharmstandard-UfaVITA. Faslodex by AstraZeneca has the worst dynamics (-34%.)

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2017 – November 2018)